Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 3/28/2024
Go back to Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
September 14, 2016 8:50 AM EDT
Leerink affirms Exelixis (Nasdaq: EXEL) at Outperform with a price target of $12 after the company announced that the... More